4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $29.8750.

Several equities research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Jefferies Financial Group reissued a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, May 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th.

4D Molecular Therapeutics Stock Performance

FDMT opened at $9.23 on Wednesday. 4D Molecular Therapeutics has a 1 year low of $3.68 and a 1 year high of $12.34. The company’s 50 day simple moving average is $9.50 and its 200 day simple moving average is $9.22. The stock has a market capitalization of $482.54 million, a PE ratio of -3.59 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. As a group, sell-side analysts expect that 4D Molecular Therapeutics will post -3.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Wexford Capital LP purchased a new stake in 4D Molecular Therapeutics during the 3rd quarter worth $41,000. Daiwa Securities Group Inc. lifted its stake in shares of 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after purchasing an additional 6,186 shares in the last quarter. Abich Financial Wealth Management LLC acquired a new position in shares of 4D Molecular Therapeutics during the third quarter worth about $80,000. Susquehanna Portfolio Strategies LLC purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter worth about $77,000. Finally, Martingale Asset Management L P boosted its position in shares of 4D Molecular Therapeutics by 12.4% in the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after buying an additional 1,303 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.